Sökning: WFRF:(Batyrbekova Nurgul)
> (2023) >
Population-based re...
Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease
-
- Novitzky-Basso, Igor (författare)
- Princess Margaret Canc Ctr, Toronto, ON, Canada.;Univ Toronto, Dept Med, Toronto, ON, Canada.
-
- Schain, Frida (författare)
- Janssen Global Serv, Stockholm, Sweden.;Schain Res AB, Bromma, Sweden.;Karolinska Inst, Dept Med, Div Hematol, Stockholm, Sweden.
-
- Batyrbekova, Nurgul (författare)
- SDS Life Sci, Stockholm, Sweden.;Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
-
visa fler...
-
- Webb, Thomas (författare)
- Janssen Global Serv, High Wycombe, England.
-
- Remberger, Mats, Professor, 1955- (författare)
- Uppsala universitet,Hematologi,Uppsala Univ Hosp, Clin Res & Dev Unit, Uppsala, Sweden.
-
- Keating, Armand (författare)
- Princess Margaret Canc Ctr, Toronto, ON, Canada.;Univ Toronto, Dept Med, Toronto, ON, Canada.
-
- Mattsson, Jonas (författare)
- Karolinska Institutet
-
visa färre...
-
Princess Margaret Canc Ctr, Toronto, ON, Canada;Univ Toronto, Dept Med, Toronto, ON, Canada. Janssen Global Serv, Stockholm, Sweden.;Schain Res AB, Bromma, Sweden.;Karolinska Inst, Dept Med, Div Hematol, Stockholm, Sweden. (creator_code:org_t)
- 2023-03-09
- 2023
- Engelska.
-
Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 21:3
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
http://kipublication...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: Chronic graft-versus-host disease (cGVHD) is a serious immune-mediated complication after allogeneic haematopoietic stem cell transplantation (HSCT), but in patients with malignancy, cGVHD development is associated with superior survival. Lack of reliable biomarkers and clinical underreporting means there is insufficient understanding of cGVHD clinical outcomes and balance between cGVHD treatment and maintaining beneficial graft-versus-tumour effects.Methods: We performed a Swedish population-wide registry study following patients who underwent allogeneic HSCT 2006-2015. cGVHD status was retrospectively classified using a real-world method based on the timing and extent of systemic immunosuppressive treatment.Results: cGVHD incidence among patients surviving >= 6 months post-HSCT (n = 1246) was 71.9%, significantly higher than previously reported. 5-year overall survival in patients surviving >= 6 months post-HSCT was 67.7%, 63.3%, and 65.3%, in non-, mild, and moderate-severe cGVHD, respectively. Non-cGVHD patients had a mortality risk almost five-fold higher compared to moderate-severe cGVHD patients 12-months post-HSCT. Moderate-severe cGVHD patients had greater healthcare utilization compared with mild and non cGVHD patients.Conclusion: cGVHD incidence was high among HSCT survivors. Non-cGVHD patients had higher mortality during the first 6 months of follow-up; however, moderate-severe cGVHD patients had more comorbidities and healthcare utilization. This study highlights the urgent need for new treatments and real-time methods to monitor effective immunosuppression after HSCT.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
PLOS ONE
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas